# US 2021/0079347 A1 · Genetically engineered t cells having improved persistence in culture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079347 A1
- Document ID: US20210079347A1
- Status: Published application
- Kind: A1
- Application number: 17/012,957
- Filed: 2020-09-04
- Published: 2021-03-18
- Earliest claimed: 2019-09-06
- Assignees: Crispr Therapeutics AG
- Applicants: CRISPR Therapeutics AG
- Inventors: Jonathan Alexander Terrett; Demetrios Kalaitzidis; Hanspeter Waldner
- Web page: https://patentgrep.com/patent/US20210079347A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0636: {T lymphocytes}
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/03: containing a transmembrane segment
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetically engineered T cells may comprise (i) a mutated gene involved in cell self-renewal; (ii) a disrupted gene involved in apoptosis; (iii) a disrupted gene involved in regulation of T cell exhaustion; or (iv) a combination of any one of (i)-(iii).

## Claims

### Claim 1

A population of genetically engineered T cells, comprising:
(i) a disrupted gene involved in cell self-renewal;
(ii) a disrupted gene involved in apoptosis;
(iii) a disrupted gene involved in regulation of T cell exhaustion; or
(iv) a combination of any one of (i)-(iii);
wherein the population of genetically engineered T cells, as compared to the non-engineered T counterparts, have one or more of the following features:(a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) a reduced apoptosis level, and (d) an enhanced frequency of activation.

### Claim 2 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the T cells comprise a combination of (i)-(iii).

### Claim 3 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein (i) comprises TET2, and optionally wherein the genetically engineered T cells do not comprise (ii), (iii) or both.

### Claim 4 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the disrupted TET2 is genetically edited in an exon selected from the group consisting of exon 1, exon 3, exon 4, exon 5, and exon 6, or a combination thereof, optionally wherein the mutated TET2 is genetically edited in exon 3, exon 4, exon 5, or exon 6.

### Claim 5 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the disrupted TET2 gene is genetically edited by CRISPR/Cas-mediated gene editing.

### Claim 6 (depends on 5)

The population of genetically engineered T cells of claim 5, wherein the disrupted TET2 gene is genetically edited by CRISPR/Cas-mediated gene editing with a guide RNA (gRNA) comprising a nucleotide sequence of SEQ ID NO: 14, 18, 22, 26, 112, 116, or 120.

### Claim 7 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein (ii) comprises FAS.

### Claim 8 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein (iii) comprises CD70.

### Claim 9 (depends on 7)

The population of genetically engineered T cells of claim 7, wherein the disrupted FAS and/or CD70 gene is genetically edited by CRISPR/Cas-mediated gene editing.

### Claim 10 (depends on 9)

The population of genetically engineered T cells of claim 9, wherein the disrupted FAS gene is genetically edited by CRISPR/Cas-mediated gene editing with a guide RNA (gRNA) comprising the nucleotide sequence of SEQ ID NO: 69, 73, 77, 81, or 85, and/or wherein the disrupted CD70 gene is genetically edited by CRISPR/Cas-mediated gene editing with a gRNA comprising the nucleotide sequence of SEQ ID NO: 34, 38, 42, 46, 50, 54, or 58.

### Claim 11 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the T cells further comprise a disrupted beta-2-microglobulin (β2M) gene.

### Claim 12 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the T cells further comprise a disrupted T cell receptor alpha chain constant region (TRAC) gene.

### Claim 13 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the T cells are further engineered to express a chimeric antigen receptor (CAR).

### Claim 14 (depends on 13)

The population of genetically engineered T cells of claim 13, wherein the CAR targets a tumor antigen.

### Claim 15 (depends on 14)

The population of genetically engineered T cells of claim 14, wherein the tumor antigen is CD19, B cell maturation antigen (BCMA), or CD70.

### Claim 16 (depends on 13)

The population of genetically engineered T cells of claim 13, wherein the T cells comprise a nucleic acid encoding the CAR, and wherein the nucleic acid is inserted in the genome of the T cells.

### Claim 17 (depends on 16)

The population of genetically engineered T cells of claim 16, wherein the disrupted TRAC gene has an insertion of the nucleotide acid encoding the chimeric antigen receptor.

### Claim 18 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the T cells are derived from primary T cells of one or more human donors.

### Claim 19 (depends on 1)

The population of genetically engineered T cells of claim 1, wherein the T cells show cytokine-dependent growth.

### Claim 20 (depends on 1)

A method for preparing the population of genetically engineered T cells of claim 1, the method comprising:
(a) providing a plurality of cells, which are T cells or precursor cells thereof;
(b) genetically editing one or more of the (i)-(iii) genes; and
(c) producing the population of genetically engineered T cells.

### Claim at position 21

21-33. (canceled)

### Claim 34 (depends on 1)

A method for preparing genetically engineered T cells expressing a chimeric antigen receptor (CAR), the method comprising:
(a) providing a plurality of T cells from a cell bank comprising genetically engineered T cells set forth in claim 1;
(b) delivering to the plurality of the T cells a nucleic acid encoding a CAR; and
(c) producing genetically engineered T cells expressing the CAR.

### Claim at position 23

35-44. (canceled)

### Claim 45 (depends on 20)

A genetically engineered T cell population, which is prepared by a method of claim 20.

### Claim 46 (depends on 13)

A method for eliminating undesired cells in a subject, the method comprising administering to a subject in need thereof T cells expressing a chimeric antigen receptor targeting to the undesired cells, wherein the T cells are set forth in claim 13.

### Claim 47

(canceled)

### Claim 48

A guide RNA (gRNA) targeting a TET2 gene, comprising a nucleotide sequence specific to exon 3 or exon 5 of the TET2 gene.

### Claim at position 28

49-64. (canceled)
